Page last updated: 2024-12-06
telmesteine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
telmesteine: RN refers to (-R)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 65946 |
| CHEMBL ID | 2107621 |
| CHEBI ID | 134866 |
| SCHEMBL ID | 637246 |
| MeSH ID | M0241640 |
Synonyms (27)
| Synonym |
|---|
| telmesteine |
| CHEBI:134866 |
| (4r)-3-ethoxycarbonyl-1,3-thiazolidine-4-carboxylic acid |
| telmesteine (inn) |
| D08565 |
| 122946-43-4 |
| reolase (tn) |
| telmesteina |
| telmesteina [inn-spanish] |
| 124i3fe35t , |
| unii-124i3fe35t |
| (-)-3-ethyl hydrogen (r)-3,4-thiazolidinedicarboxylate |
| telmesteinum [inn-latin] |
| telmesteine [inn] |
| telmesteinum |
| AKOS010385372 |
| CHEMBL2107621 |
| reolase |
| telmesteine [who-dd] |
| telmesteine [inci] |
| telmesteine [mart.] |
| SCHEMBL637246 |
| (r)-3-(ethoxycarbonyl)thiazolidine-4-carboxylic acid |
| DTXSID60153804 |
| 3,4-thiazolidinedicarboxylic acid, 3-ethyl ester, (4r)- |
| Q27251366 |
| EN300-881275 |
Research Excerpts
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| " Only 2 patients discontinued MAS063DP due to an adverse event." | ( A multicenter, randomized, vehicle-controlled clinical study to examine the efficacy and safety of MAS063DP (Atopiclair) in the management of mild to moderate atopic dermatitis in adults. Abramovits, W; Boguniewicz, M, 2006) | 0.33 |
| "MAS063DP cream was confirmed to be a safe and effective treatment for mild to moderate atopic dermatitis in adults." | ( A multicenter, randomized, vehicle-controlled clinical study to examine the efficacy and safety of MAS063DP (Atopiclair) in the management of mild to moderate atopic dermatitis in adults. Abramovits, W; Boguniewicz, M, 2006) | 0.33 |
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| " (14)C-telmesteine was rapidly absorbed after oral dosing (20 and 50 mg kg(-1)) with an oral bioavailability of >90% both in male and female rats." | ( Absorption, distribution, metabolism and excretion of telmesteine, a mucolitic agent, in rat. Kim, DH; Lee, J; Rhee, SW; Son, J, 2003) | 1.02 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " (14)C-telmesteine was rapidly absorbed after oral dosing (20 and 50 mg kg(-1)) with an oral bioavailability of >90% both in male and female rats." | ( Absorption, distribution, metabolism and excretion of telmesteine, a mucolitic agent, in rat. Kim, DH; Lee, J; Rhee, SW; Son, J, 2003) | 1.02 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (2)
| Class | Description |
|---|---|
| organonitrogen compound | Any heteroorganic entity containing at least one carbon-nitrogen bond. |
| organooxygen compound | An organochalcogen compound containing at least one carbon-oxygen bond. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 28.05
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (28.05) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 5 (71.43%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 2 (28.57%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||